Publication | Closed Access

Epigallocatechin-3-O-gallate (EGCG) attenuates FFAs-induced peripheral insulin resistance through AMPK pathway and insulin signaling pathway in vivo

Insulin ResistanceMetabolic SyndromeInsulin SignalingSignal TransductionAmpk PathwayMedicineInsulin ManagementDiabetesPhysiologyMetabolic RegulationDiabetes MellitusEndocrinologyPharmacologyCell BiologyCell SignalingHealth Sciences